Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est

Benzinga Newsdesk www.benzinga.com Negative 64.5%

Neg 64.5% Neu 0% Pos 0%

Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.